HEALX LIMITED

• ⚠

  Confirmation statement overdue

  Due 2026-05-14.

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

• Turnover

  —

  Not reported

• Cash

  +592.4%

  £2,991,505 → £20,713,724

• Net assets

  +441%

  £4,035,324 → £21,830,359

• Employees

  -17.9%

  67 → 55

• Operating profit

  +22.4%

  -£17,965,263 → -£13,945,025

• Profit before tax

  +23.4%

  -£17,973,936 → -£13,770,647

• Wages

  -24.4%

  £4,869,819 → £3,682,190

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers

Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

1. HEALX LIMITED 2015-01-07 → present
2. HEALX3 LIMITED 2014-04-30 → 2015-01-07

Accounting basis

IFRS

Reporting scope

Consolidated group

Auditor

PricewaterhouseCoopers LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“The financial statements have been prepared on a going concern basis, which assumes that the Group and Company will continue in operation for the foreseeable future. There was a net loss of £11.7m (2023: £15.6m) for the year ended 31 December 2024 and as of 31 December 2024, the Group and Company had cash and cash equivalents of £20.7m (2023: £3.0m). The Group closed the year with net assets of £21.8m (2023: £4.0m).”

Group structure

1. HEALX LIMITED · parent
   1. Healx Technology Limited 100% · Ireland · Its principal activity is to support the Group's regulatory strategy in Europe by enabling Healx to register with the European Medicines Agency (EMA) as a Small and Medium-sized Enterprise (SME). This designation provides the group with significant benefits, including regulatory fee reductions of up to 90%, access to prioritised scientific advice, and dedicated EMA support.

Significant events

• “In 2024, Healx made significant strides across its portfolio, technology, and partnerships. The company strategically refined its focus around three core therapeutic areas: rare oncology, rare renal, and rare neurodevelopmental disorders. By the end of the year, Healx was advancing seven therapeutic programmes within these domains.”
• “Notably, a new asset, HLX-1502, was successfully transitioned from the preclinical stage to clinical development for the treatment of Neurofibromatosis Type 1 (NF1). To support this advancement, Healx secured US Orphan Drug and Fast Track Designations, obtained FDA IND approval, and has since initiated a Phase II clinical trial in the US.”
• “Healx's TechBio platform has continued to evolve in alignment with portfolio priorities. This year, key efforts have centered on advancing the Virtual Screening platform to support the discovery of a NCE for ADPKD, and enhancing the phenotypic profiling capabilities to drive the development of a new NCE for NF1.”
• “Healx maintained several strategic collaborations with biotech, pharmaceutical, academic, and patient advocacy groups. Notably, in November 2024, Healx entered into a collaboration with Sanofi to identify new indications for one of Sanofi's proprietary assets.”
• “In August 2024, Healx announced it had secured $47m (£36m) in a Series C funding round, which generated strong inbound interest. As a result, the company has raised an additional $13m (£10m) in a Series C extension to date.”
• “In December 2024, Dr. Jonathan Milner, a leading figure in the life sciences sector and founder of Abcam, was appointed non-executive chairman of Healx.”
• “Healx's headcount reached 54 by year-end, closely aligning with its 2023 figure of 51, reflecting its strategy of maintaining operational efficiency and optimizing capital allocation to high-value areas of the business.”
• “During the year, the Group and Company issued 10,527 ordinary shares and 5,364,135 preference shares at a price of £0.21 and £5.26683 per share respectively, raising total proceeds of £28.3m. There were no capital reductions during the financial year.”
• “The Group and Company issued 893,056 preference shares, resulting in total gross proceeds of £4.7m. The shares were issued at a premium, and the proceeds will be used to support the Company's ongoing working capital requirements.”
• “In March 2025, the Board decided to close the Cambridge Lab facility, aligning with a strategic focus on existing preclinical and clinical stage assets.”
• “On 28 July 2025, Healx Limited entered into a transaction with Vuja De Sciences, Inc. (Vuja De), a Delaware corporation. The deal is structured as a Joint Venture via Healx USA Holdings LLC, formed by Healx. VujaDe's shareholders contributed all their VujaDe stock to Healx USA Holdings LLC. Healx contributed $3m cash into Healx USA Holdings LLC to be used for the progression of Vuja De's development program. This transaction brings a second Rare Oncology program into Healx portfolio.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

8

last 12 months

Capital events

2

last 24 months

Officers appointed

1

last 12 months

Officers resigned

0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.